Severe or lethal toxicities upon capecitabine intake: is DPYD genetic polymorphism the ideal culprit?

Trends in Pharmacological Sciences

Volumn 28, Issue 12, 2007, Pages 597-598

  Mercier, Cédric ^a   Ciccolini, Joseph ^a  

^a TIMONE HOSPITAL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; FLUOROURACIL; GEMCITABINE; OXALIPLATIN;

BREAST CANCER; BREAST METASTASIS; COLORECTAL CANCER; DIARRHEA; DISEASE COURSE; DISEASE SEVERITY; DRUG FATALITY; DRUG MECHANISM; DRUG METABOLISM; DRUG SAFETY; DRUG TOLERABILITY; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME DEFICIENCY; FOOD AND DRUG ADMINISTRATION; GENETIC POLYMORPHISM; HAND FOOT SYNDROME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LETTER; MULTIPLE ORGAN FAILURE; NEUTROPENIA; OUTCOME ASSESSMENT; PANCYTOPENIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; SEPSIS; TREATMENT INDICATION; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 36549011401     PISSN: 01656147     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tips.2007.09.009     Document Type: Letter

References (10)

1. Biganzoli L., et al. Moving forward with capecitabine: a glimpse of the future. Oncologist 7 (2002) 29-35
2. van Kuilenburg A.B. Dihydropyrimidine dehydrogenase and the efficacy and toxicity of 5-fluorouracil. Eur. J. Cancer 40 (2004) 939-950
3. Maitland M.L., et al. TPMT, UGT1A1 and DPYD: genotyping to ensure safer cancer therapy?. Trends Pharmacol. Sci. 27 (2006) 432-437
4. Mercier C., and Ciccolini J. Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy. Clin. Colorectal Cancer 6 (2006) 288-296
5. Ciccolini J., et al. Toxic death-case after capecitabine + oxaliplatin (XELOX) administration: probable implication of dihydropyrimidine deshydrogenase deficiency. Cancer Chemother. Pharmacol. 58 (2006) 272-275
6. Ciccolini J., et al. A rapid and inexpensive method for anticipating severe toxicity to fluorouracil and fluorouracil-based chemotherapy. Ther. Drug Monit. 28 (2006) 678-685
7. Largillier R., et al. Pharmacogenetics of capecitabine in advanced breast cancer patients. Clin. Cancer Res. 12 (2006) 5496-5502
8. Saif M.W., and Diasio R. Is capecitabine safe in patients with gastrointestinal cancer and dihydropyrimidine dehydrogenase deficiency?. Clin. Colorectal Cancer 5 (2006) 359-362
9. Saif M.W., et al. Hand-foot syndrome variant in a dihydropyrimidine dehydrogenase-deficient patient treated with capecitabine. Clin. Colorectal Cancer 6 (2006) 219-223
10. Mackean M., et al. Phase I and pharmacologic study of intermittent twice-daily oral therapy with capecitabine in patients with advanced and/or metastatic cancer. J. Clin. Oncol. 16 (1998) 2977-2985